1Ohnishi H,Yokoyama A,Kondo K,et al.Comparative Study of KL-6,Surfactant Protein-A,Surfactant Protein-D,and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung Diseases.Am J Respir Crit Care Med,2002;165:378～381
2Wong RC,Klingberg S,Wilson R.CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis.J Rheumatol,2002;29:
3Ogawa N,Shimoyama K,Kawabata H,et al.Clinical significance of serum KL-6 and SP-D for the diagnosis and treatment of interstitial lung disease in patients with diffuse connective tissue disorders.Ryumachi,2003;43:19～28
4Ihn H,Asano Y,Kubo M,et al.Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis:correlation with interstitial lung disease.Rheumatology (Oxford),2002;41:1268～1272
5Amoura Z,Duhaut P,Costedoat N,et al.Elevation of CA15-3 and carcino embryonic antigen in myositis with interstitial lung diseases.Arthritis Rheumatism,2002;47:s612
6Totani Y,Demura Y,Ameshima S,et al.Silicosis characterized by increasing serum CA 19-9 in parallel with progression of lung fibrosis.Nihon Kokyuki Gakkai Zasshi,2000;38:137-142
7Otsuka M,Takahashi H,Fujisima T,et al.New serum markers to monitor treatment of acute exacerbation of interstitial lung disease.Nihon Kokyuki Gakkai Zasshi,2001;39:298-302
8Yokoyama A,Kohno N,Hamada H,et al.Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis.Am J Respir Crit Care Med,1998;158:1680-1684
9Bandoh S,Fujita J,Ohtsuki Y,et al.Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis.Ann Rheum Dis,2000;59:257-262
10Fukaya S,Oshima H,Kato K,et al.KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases.Rheumatol Int,2000;19:223-225
5Douglas WW,Tazelaar HD, Hartman TE,et al. Polymyositisdermatomyositis-assoeiated interstitial lung disease. Am J Respir Crit Care Meal,2001,164: 1182-1185.
6Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol, 2004, 49: 235- 244.
7Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis, 2004,63: 297-301.
8Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis:an association with malignancy. Rheumatology(Oxford), 2007,46 : 25-28.
9Kohno N. Serum marker KL-6/MUC1 for diagnosis and management of interstitial pneumonitis. J Med Invest, 1999, 46:151-158.
10Kida Y, Maeshima E, Furukawa K, et al. A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer. Mod Rheumatol, 2007,17 : 262-264.
